A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes
Íñigo Angulo‐Barturen(Euskadiko Parke Teknologikoa), Domingo Gargallo‐Viola(GlaxoSmithKline (United Kingdom)), Ian Bathurst(Medicines for Malaria Venture), Elena Jiménez(GlaxoSmithKline (Spain)), Philip J. Rosenthal(University of California, San Francisco), Teresa Mulet(GlaxoSmithKline (Spain)), Santiago Ferrer(GlaxoSmithKline (Spain)), Javier Regadera(Universidad Autónoma de Madrid), Federico G. De las Heras(GlaxoSmithKline (Spain)), Alfonso Mendoza(GlaxoSmithKline (Spain)), Joaquín Rullás(GlaxoSmithKline (Spain)), Esperanza Herreros(GlaxoSmithKline (Spain)), David L. Pompliano(GlaxoSmithKline (United States)), Marı́a Belén Jiménez-Dı́az(Euskadiko Parke Teknologikoa)
Cited by 164
Related Papers
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria
|Proceedings of the National Academy of Sciences|2011|379
Malaria Transmission, Infection, and Disease at Three Sites with Varied Transmission Intensity in Uganda: Implications for Malaria Control
|American Journal of Tropical Medicine and Hygiene|2015|236
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study
|The Lancet Infectious Diseases|2021|231
Novel serologic biomarkers provide accurate estimates of recent <i>Plasmodium falciparum</i> exposure for individuals and communities
|Proceedings of the National Academy of Sciences|2015|219
Improved Murine Model of Malaria Using<i>Plasmodium falciparum</i>Competent Strains and Non-Myelodepleted NOD-<i>scid IL2R</i>γ<sup><i>null</i></sup>Mice Engrafted with Human Erythrocytes
|Antimicrobial Agents and Chemotherapy|2009|189